Trial reportThe Journal of urology2017
Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.
Trial report in The Journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA-A secondary analysis.Neurourology and urodynamics · 2023Trial
- Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?International urogynecology journal · 2023Trial
- Trial
- Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.European urology · 2018Trial
- Urinary Cytokines in Predicting Intradetrusor Onabotulinumtoxin-A Response.Neurourology and urodynamics · 2026Article
- Depression mediates the association between lipid accumulation products and overactive bladder.Scientific reports · 2025Article
- Botulinum toxin A in idiopathic overactive bladder: a narrative review of 5410 cases.The Canadian journal of urology · 2025Review
- Outcomes following intradetrusor onabotulinumtoxinA in a national cohort of nursing home residents.BJUI compass · 2025Article
- Predicting success using response after lead implantation with sacral neuromodulation for urgency incontinence.Neurourology and urodynamics · 2024Article
- Evaluation and management of urinary incontinence in nursing home residents: unique considerations for an at-risk population.Gynecology and pelvic medicine · 2024Review
- Quality of Life in Female Patients with Overactive Bladder after Botulinum Toxin Treatment.Toxins · 2023Article
- Neural networks outperform expert humans in predicting patient impressions of symptomatic improvement following overactive bladder treatment.International urogynecology journal · 2023Article
- Third-line therapy for overactive bladder in the elderly: Nuances and considerations.Neurourology and urodynamics · 2022Review
- Predicting outcomes after intradetrusor onabotulinumtoxina for non-neurogenic urgency incontinence in women.Neurourology and urodynamics · 2022Article
- Sacral neuromodulation for symptomatic chronic urinary retention in females: do age and comorbidities make a difference?International urogynecology journal · 2021Article
- Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?International urogynecology journal · 2021Article
- [Analysis of the effectiveness of urinary incontinence management in a geriatric rehabilitation].Zeitschrift fur Gerontologie und Geriatrie · 2020Article
- Variation in bony landmarks and predictors of success with sacral neuromodulation.International urogynecology journal · 2019Article
- Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.International urogynecology journal · 2018Review
- Failures of Sacral Neuromodulation for Incontinence.JAMA surgery · 2018Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 10 institutions in 1 country.
Funding
Abstract
purposeWe sought to identify clinical and demographic characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation therapies. MATERIALS AND
methodsWe analyzed data from the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation versus BoTulinum Toxin Assessment) trial. Baseline participant characteristics and clinical variables were associated with 2 definitions of treatment response, including 1) a reduction in mean daily urgency incontinence episodes during 6 months and 2) a 50% or greater decrease in urgency incontinence episodes across 6 months. The OAB-S (Overactive Bladder-Satisfaction) questionnaire was used to assess satisfaction.
resultsA greater reduction in mean daily urgency incontinence episodes was associated with higher HUI-3 (Health Utility Index-3) scores in the onabotulinumtoxinA group and higher baseline incontinence episodes (each p <0.001) in the 2 groups. Increased age was associated with a lesser decrease in incontinence episodes in the 2 groups (p <0.001). Increasing body mass index (adjusted OR 0.82/5 points, 95% CI 0.70-0.96) was associated with reduced achievement of a 50% or greater decrease in incontinence episodes after each treatment. Greater age (adjusted OR 0.44/10 years, 95% CI 0.30-0.65) and a higher functional comorbidity index (adjusted OR 0.84/1 point, 95% CI 0.71-0.99) were associated with reduced achievement of a 50% or greater decrease in urgency incontinence episodes in the onabotulinumtoxinA group only (p <0.001 and 0.041, respectively). In the onabotulinumtoxinA group increased satisfaction was noted with higher HUI-3 score (p = 0.002) but there was less satisfaction with higher age (p = 0.001).
conclusionsOlder women with multiple comorbidities, and decreased functional and health related quality of life had decreased treatment response and satisfaction with onabotulinumtoxinA compared to sacral neuromodulation for refractory urgency incontinence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.